drugset / Trial / NCT05613166
Adjunctive Everolimus Treatment of Refractory Epilepsy
Phase 2
Unknown
108 enrolled
National Institute on Drug Dependence, China
Peking University · collabShengjing Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This project is a prospective, randomized, placebo-controlled, double-blind study that will evaluate the clinical efficacy of everolimus as an adjunctive treatment in adult patients diagnosed with refractory epilepsy.
Timeline
- Start
- 2022-11
- Primary completion
- 2023-01
- Completion
- 2023-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 2.5 mg | Oral |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 7.5 mg | Oral |